Can levosimendan reduce ECMO weaning failure in cardiogenic shock?: a cohort study with propensity score analysis

Enrique Guilherme 1*, Matthias Jacquet-Lagrèze 1,2, Matteo Pozzi 3, Felix Achana 4, Xavier Armoiry 5,6 and Jean-Luc Fellahi 1,2

Abstract

Background: Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) has been increasingly used over the last decade in patients with refractory cardiogenic shock. ECMO weaning can, however, be challenging and lead to circulatory failure and death. Recent data suggest a potential benefit of levosimendan for ECMO weaning. We sought to further investigate whether the use of levosimendan could decrease the rate of ECMO weaning failure in adult patients with refractory cardiogenic shock.

Methods: We performed an observational single-center cohort study. All patients undergoing VA-ECMO from January 2012 to December 2018 were eligible and divided into two groups: group levosimendan and group control (without levosimendan). The primary endpoint was VA-ECMO weaning failure defined as death during VA-ECMO treatment or within 24 h after VA-ECMO removal. Secondary outcomes were mortality at day 28 and at 6 months. The two groups were compared after propensity score matching. P < 0.05 was considered statistically significant.

Results: Two hundred patients were analyzed (levosimendan group: n = 53 and control group: n = 147). No significant difference was found between groups on baseline characteristics except for ECMO duration, which was longer in the levosimendan group (10.6 ± 4.8 vs. 6.5 ± 4.7 days, p < 0.001). Levosimendan administration started 6.6 ± 5.4 days on average following ECMO implantation. After matching of 48 levosimendan patients to 78 control patients, the duration of ECMO was similar in both groups. The rate of weaning failure was 29.1% and 35.4% in levosimendan and control groups, respectively (OR: 0.69, 95%CI: 0.25–1.88). No significant difference was found between groups for all secondary outcomes.

Conclusion: Levosimendan did not improve the rate of successful VA-ECMO weaning in patients with refractory cardiogenic shock.

Trial registration: ClinicalTrials.gov, NCT04323709.

Keywords: Levosimendan, VA-ECMO, Cardiogenic shock, ECMO weaning failure, Circulatory failure
**Introduction**

Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) is a temporary mechanical circulatory support that has been increasingly used over the last decade to restore and maintain adequate end-organ perfusion and improve outcomes in patients with refractory cardiogenic shock [1, 2]. Nevertheless, the weaning of VA-ECMO should be daily questioned, as several studies reported severe complications like cannula-related infections [3], bleeding [4], and thromboembolic events [5] associated with prolonged VA-ECMO durations. Dobutamine is currently used to improve myocardial contractility during VA-ECMO, aiming to enhance left ventricular ejection and aortic valve opening and also to shorten ECMO duration. Numerous data suggest however an increased risk of mortality related to myocardial ischemia and arrhythmias [6, 7]. Levosimendan is a calcium-sensitizing inotropic agent with systemic, coronary, and pulmonary vasodilatory properties and also specific cardioprotective effects with respect to myocardial oxygen balance [8–10]. It has been approved for the treatment of acute decompensated heart failure, but its efficacy in cardiogenic shock remains questionable [11]. The use of levsimendan in patients undergoing VA-ECMO might be of interest both to reduce the duration of mechanical support and to minimize severe complications. A potential benefit in terms of VA-ECMO weaning success and increased survival has been recently suggested in low cardiac output syndrome following cardiac surgery [12] with the improvement of endothelial function and hemodynamics [13]. We therefore sought to evaluate whether the use of levsimendan could improve weaning of VA-ECMO support in a large cohort of patients undergoing refractory cardiogenic shock.

**Methods**

**Study design and patient population**

We conducted a retrospective observational study between January 2012 and December 2018 at Louis Pradel University Hospital (Hospices Civils de Lyon, France). The study protocol was approved by our Institutional Review Board (N°20-54; Chair: Prof. JF Guerin) and registered with ClinicalTrial.gov (NCT04323709). Given the retrospective and non-interventional design of the study, the need for written informed consent was waived. All consecutive adult patients admitted to the cardiothoracic intensive care unit (ICU) who underwent VA-ECMO for refractory cardiogenic shock were eligible for the study. Exclusion criteria were age < 18 years, VA-ECMO duration < 48 h, VA-ECMO for refractory cardiac arrest, right heart or veno-venous ECMO, and VA-ECMO for circulatory failure following lung transplantation.

**Data collection**

The following data were collected at the admission: age, gender, body mass index, Simplified Acute Physiology Score (SAPS-II), Sequential Organ Failure Assessment (SOFA), hypertension, diabetes, hypercholesterolemia, smoking status, history of stroke or congestive heart failure, coronary or peripheral artery disease, renal failure with dialysis, left ventricular ejection fraction (LVEF), tricuspid annular plane systolic excursion (TAPSE), mean arterial pressure, heart rate, central venous pressure, ScvO2, presence of an intra-aortic balloon pump, and biochemical parameters. During the hospitalization, the following variables were collected: the reason for initiation of VA-ECMO and VA-ECMO characteristics (duration, type, flow (L/min), RPM, FiO2), length of stay in ICU, catecholamines and inotrope maximal doses and durations of administration, and patients receiving heart transplantation or left ventricular assist device (LVAD). In patients receiving levsimendan, the timing of administration regarding VA-ECMO initiation was also collected.

**Patients’ management**

During the study period, all patients were managed according to international guidelines for cardiogenic shock [14]. Timings of administration of levsimendan (Zimino®, Orion Pharma, Issy-les-Moulineaux, France) and catecholamines were at the entire discretion of the physicians. The administration of levsimendan was started at a dose of 0.1 μg/kg/min for 1 h, followed by a continuous infusion of 0.1 to 0.2 μg/kg/min for 24 h. VA-ECMO flow rate was initially set at the theoretical cardiac output owing to the body surface area of the patient (2.2 L/min/m2). Inotropic support was usually provided in order to maintain both a left ventricular ejection and an aortic valve opening. Anticoagulation with unfractionated heparin was used to maintain anti-Xa factor activity between 0.30 and 0.35 IU/ml during mechanical support. Serial transesophageal echocardiography was performed after a progressive reduction of VA-ECMO flow to a minimum of 1.0–1.5 L/min to assess myocardial recovery. When the weaning trial was hemodynamically well tolerated without the need for increasing inotropic or vasoactive support and echocardiographic criteria were fulfilled (LVEF > 20–25%, time-velocity integral > 10 cm, lateral mitral annulus peak systolic velocity > 6 cm/s, satisfactory right ventricular systolic function without dilatation [15]), the weaning procedure was performed.

**Study endpoints**

The primary endpoint was VA-ECMO weaning failure defined as death occurring during VA-ECMO support or within 24 h after VA-ECMO removal [12, 16]. Secondary endpoints were mortality at day 28 and at 6 months after VA-ECMO implantation. Based on the
available literature [17–24] and on the analysis of patient outcomes in our institutional database [25, 26], we classified indications for VA-ECMO into three categories (high, intermediate, or low) according to the potential for myocardial recovery.

Statistical analysis
Continuous variables were summarized as mean ± standard deviation and compared using Student’s t test or Mann–Whitney U test depending on their normality. Categorical variables were summarized as counts and percentages and compared using Pearson’s chi-squared test or Fisher’s exact test, as appropriate. Survival at 28 days was reported with Kaplan–Meier curves and compared between the two groups with the log-rank test. We conducted a multivariable logistic regression with propensity score matching [27, 28], which was defined as the probability of exposure to levosimendan. We selected only the covariates most likely to introduce a confounding bias based on clinical expertise and inputs from the literature [20, 29–31]: potential for myocardial recovery, age, gender, SAPS-II, SOFA, LVEF, duration of VA-ECMO, and lactate level. Next, we performed matching with replacement between patients from the levosimendan group and those from the control group in a 1:10 ratio. Finally, we undertook multivariate weighted logistic regression with weaning failure as an outcome variable and the treatment group and the matched variables as explanatory variables. Results were reported as odds ratios (ORs) together with 95% confidence intervals (CIs) assuming a 5% level of statistical significance. All analyses were conducted in STATA 16.0 (Stata Corp, College Station, Texas 77845 USA).

Results
Population
The flow chart of the study is depicted in Fig. 1. Of 399 patients admitted to the ICU who received VA-ECMO, 199 patients were excluded, leaving a total of 200 patients who met eligibility criteria: 53 in the group levosimendan and 147 in the control group. The use of levosimendan in that specific indication started in 2013 admission.

Baseline characteristics and outcomes in the unmatched cohort
No significant difference in baseline characteristics was found between groups except for VA-ECMO duration which was longer in the levosimendan group (10.6 ± 4.8 vs. 6.5 ± 4.7 days, p < 0.001) (Table 1). Indications for VA-ECMO were mainly represented by post-cardiotomy low cardiac output syndrome (29.5%), acute myocardial infarction (22.5%), and graft dysfunction (16.5%). Mean LVEF at admission was 19.6 ± 11.3%, and 30.8% of patients had a significant right ventricular failure. Peripheral VA-ECMO cannulation was performed in 87.5% of cases and 27% of patients had IABP associated with VA-ECMO. Fifty-three (26.5%) patients received levosimendan, the administration starting at 6.6 ± 5.4 days after implantation. Rates of weaning failure were 28.3% and 29.9% in the levosimendan and control groups, respectively (OR 0.92; 95% CI 0.46–1.85). The mortality rate at 28 days was 44.2% in the levosimendan group and 37.5% in the control group (OR 0.69; 95% CI 0.39–2.51) (Fig. 3). Heart transplantation was more frequent in the levosimendan group (13.7% vs. 4.0% respectively, p = 0.017), as was LVAD implantation (11.3% vs. 2.7% respectively, p = 0.014). SOFA score and LVEF at admission were the only covariates associated with weaning failure after multivariate analysis (see Appendix).

Baseline characteristics and outcomes after propensity score analysis
After matching of 48 patients in the levosimendan group to 78 in the control group (Fig. 1), the balance of covariates was improved with no statistical difference on any of the covariates, including VA-ECMO duration (Table 2). Rates of weaning failure were 29.1% and 35.4% in the levosimendan and control groups, respectively (OR 0.69; 95% CI 0.25–1.88). No significant difference was found between both groups for all secondary outcomes. Rates of death at 28 days were 41.0% and 41.6% in the levosimendan and the control groups, respectively (OR 1.08; 95% CI 0.42–2.81). Rates of death at 6 months were 50.0% and 54.3% in the levosimendan and control groups, respectively (OR 0.79; 95% CI 0.30–2.07).

Discussion
The main finding of the present study is that levosimendan did not significantly improve the rate of VA-ECMO weaning success in ICU patients with refractory cardiogenic shock. Moreover, no benefit of levosimendan was found on mortality at 28 days and 6 months after admission.

The theoretical specific features of levosimendan are of interest in such a clinical setting: (1) inotropic effect with respect to myocardial oxygen balance; (2) lack of pro-arrhythmic effect or interaction with beta-blockers; (3) systemic, pulmonary, and coronary vasodilation; and (4) cardioprotective effect against ischemia/reperfusion injury as well as anti-inflammatory properties [10]. Moreover, its long-lasting action (up to 8–9 days) due to circulating active metabolites could be particularly useful by providing a continuous support in the critical immediate post-VA-ECMO period. A first pilot case-control study including 17 patients undergoing VA-ECMO for
Fig. 1 The study flow chart

Population (N=399)
All patients with VA-ECMO between January 2012 and December 2018

Exclusion criteria (N=199)
- Refractory cardiac arrest (N=100)
- ECMO < 48h (N=42)
- Right Heart or VV-ECMO (N=32)
- Lack of data in medical record (N=13)
- Lung transplant (N=8)
- Age < 18 years (N=4)

Study Patients (N=200)

Levosimendan Group (N=53)
Control Group (N=147)

Study Patients after matching (N=126)

Levosimendan Group (N=48)
Control Group (N=78)

Fig. 2 Proportion of patients receiving levosimendan over the study period (2012–2018)
### Table 1 Patients demographic and clinical characteristics

| Clinical characteristics at ICU admission | All (n = 200) | Levosimendan (n = 53) | Control (n = 147) | p value |
|------------------------------------------|--------------|-----------------------|-------------------|---------|
| Age (years)                              | 53 ± 13.5    | 53.9 ± 14.3           | 52.6 ± 13.3       | 0.575   |
| Male                                     | 129 (64.5)   | 33 (62.3)             | 96 (65.3)         | 0.692   |
| BMI (kg/m²)                              | 25.3 ± 5.4   | 25.3 ± 5.6            | 25.3 ± 5.3        | 0.975   |
| SAPS-II                                  | 52.2 ± 14.3  | 53.5 ± 10.8           | 51.7 ± 15.4       | 0.349   |
| SOFA                                     | 11.7 ± 2.1   | 11.5 ± 1.5            | 11.8 ± 2.2        | 0.459   |
| Comorbidities                            |              |                       |                   |         |
| Hypertension                             | 62 (31)      | 18 (34)               | 44 (29.9)         | 0.587   |
| Diabetes                                 | 36 (18)      | 11 (20.8)             | 25 (17)           | 0.430   |
| History of congestive heart failure     | 101 (51)     | 26 (50)               | 75 (51.4)         | 0.865   |
| Coronary artery disease                  | 88 (44)      | 27 (50.9)             | 61 (41.5)         | 0.235   |
| Peripheral artery disease                | 11 (5.5)     | 4 (7.5)               | 7 (4.8)           | 0.446   |
| History of stroke                        | 14 (7)       | 5 (9.4)               | 9 (6.1)           | 0.418   |
| Smoking                                  | 71 (35.5)    | 18 (34)               | 53 (36.1)         | 0.785   |
| Dyslipidemia                             | 49 (24.5)    | 14 (26.4)             | 35 (23.8)         | 0.705   |
| Renal failure with dialysis              | 15 (7.5)     | 3 (5.6)               | 12 (8.1)          | 0.553   |
| Indication for VA-ECMO                   |              |                       |                   | 0.068   |
| Post-cardiomyectomy                      | 59 (29.5)    | 18 (34)               | 41 (27.9)         |         |
| Acute myocardial infarction              | 45 (22.5)    | 17 (32.1)             | 28 (19)           |         |
| Graft dysfunction                        | 33 (16.5)    | 3 (5.7)               | 30 (20.4)         |         |
| Dilated cardiomyopathy                   | 15 (7.5)     | 5 (9.4)               | 10 (6.8)          |         |
| Intoxication                             | 14 (7)       | 0 (0)                 | 14 (9)            |         |
| Fulminant myocarditis                    | 13 (6.5)     | 3 (5.7)               | 10 (6.8)          |         |
| Pulmonary embolism                       | 6 (3)        | 2 (3.8)               | 4 (2.7)           |         |
| Septic cardiomyopathy                    | 6 (3)        | 2 (3.8)               | 4 (2.7)           |         |
| Others                                   | 9 (4.5)      | 3 (5.6)               | 6 (4)             |         |
| Potential for myocardial recovery        |              |                       |                   | 0.264   |
| High                                     | 39 (19.5)    | 7 (13.2)              | 32 (21.8)         |         |
| Intermediate                             | 86 (43)      | 22 (41.5)             | 64 (43.5)         |         |
| Low                                      | 75 (37.5)    | 24 (45.3)             | 51 (34.7)         |         |
| Hemodynamic parameters at admission      |              |                       |                   |         |
| LVEF (%)                                 | 19.6 ± 11.3  | 18 ± 11.1             | 20.2 ± 11.4       | 0.241   |
| TAPSE < 12 (mm)                          | 45 (30.8)    | 15 (34.8)             | 30 (29.1)         | 0.489   |
| MAP (mmHg)                               | 69 ± 11      | 70 ± 11               | 69 ± 11           | 0.643   |
| HR (beats/min)                           | 103 ± 24     | 108 ± 21              | 102 ± 25          | 0.145   |
| CVP (mmHg)                               | 10.6 ± 5     | 10.8 ± 5.5            | 10.6 ± 4.9        | 0.798   |
| ScvO₂ (%)                                | 62 ± 11      | 60 ± 12               | 63 ± 11           | 0.065   |
| VA-ECMO characteristics                  |              |                       |                   |         |
| VA-ECMO duration (days)                  | 7.6 ± 5      | 10.6 ± 4.8            | 6.5 ± 4.7         | < 0.001 |
| Flow rate (L/min)                        | 3.5 ± 0.8    | 3.4 ± 0.8             | 3.5 ± 0.8         | 0.835   |
| Rotation (round/min)                     | 4360 ± 1711  | 4480 ± 1724           | 4312 ± 1710       | 0.547   |
| FiO₂ (%)                                 | 59 ± 12      | 58 ± 12               | 59 ± 13           | 0.977   |
| Peripheral VA-ECMO canulation            | 175 (87.5)   | 48 (90.6)             | 127 (86.4)        | 0.496   |
| IABP associated to VA-ECMO               | 54 (27)      | 16 (30.1)             | 38 (25.8)         | 0.542   |
The cardiogenic shock of varying etiologies was published in 2013 and found some benefit when levosimendan was used 24 h before the planned weaning [32]. However, the small sample size of that study (6 patients only received levosimendan) did not allow any definite conclusion. More recently, the study conducted by Distelmaier et al. also suggested a beneficial effect of levosimendan on a large population of 240 cardiac surgical patients experiencing postoperative low cardiac output syndrome [12]. Indeed, a strong association was found between levosimendan and both successful VA-ECMO weaning and short- and long-term mortality. Conversely, the study by Jacky et al. conducted in the setting of cardiac surgery compared levosimendan to milrinone without

| Biological parameters | All (n = 200) | Levosimendan (n = 53) | Control (n = 147) | p value |
|-----------------------|--------------|----------------------|------------------|---------|
| Hemoglobin level (g/dL) | 113 ± 25     | 114 ± 26             | 113 ± 24         | 0.717   |
| International normalized ratio | 1.6 ± 0.6 | 1.5 ± 0.5            | 1.6 ± 0.6        | 0.338   |
| Arterial blood pH | 7.26 ± 0.1   | 7.27 ± 0.1           | 7.26 ± 0.1       | 0.652   |
| Lactate level (mmol/L) | 7.2 ± 5.1    | 6.4 ± 4.7            | 7.5 ± 5.3        | 0.178   |
| Creatinine level (μmol/L) | 152 ± 78   | 150 ± 77             | 153 ± 79         | 0.843   |
| Total bilirubin level (μmol/L) | 23 ± 17    | 22 ± 17              | 24 ± 17          | 0.457   |
| ASAT (U/L) | 763 ± 1819 | 717 ± 1454           | 781 ± 1945       | 0.828   |
| ALAT (U/L) | 390 ± 907  | 295 ± 610            | 426 ± 998        | 0.372   |

Catecholamines during ICU stay

| Norepinephrine max dose (μg/kg/min) | 1.49 ± 1.05 | 1.56 ± 1.07 | 1.47 ± 1.04 | 0.586   |
| Norepinephrine duration (days) | 10.9 ± 8.7  | 12.8 ± 7.2   | 10.2 ± 9.2   | 0.068   |
| Dobutamine max dose (μg/kg/min) | 9.7 ± 4.6   | 10.4 ± 10.2  | 9.5 ± 4.3    | 0.309   |
| Dobutamine duration (days) | 9.1 ± 7.9   | 10.3 ± 10.2  | 8.6 ± 6.6    | 0.203   |

ICU intensive care unit, BMI body mass index, SAPS-II simplified acute physiology score, SOFA sequential organ failure assessment, LVEF left ventricular ejection fraction, TAPSE tricuspid annular plane systolic excursion, MAP mean arterial pressure, HR heart rate, CVP central venous pressure, ScvO2 central venous oxygen saturation, FiO2 fractional inspired oxygen, IABP intra-aortic balloon pump, ASAT aspartate aminotransferase, ALAT alanine aminotransferase

Fig. 3 Kaplan-Meier survival curves in the unmatched cohort of patients (N = 200)
any difference between the two drugs [16]. Recently, Vally et al. reported that exposure to levosimendan might be independently associated with beneficial effects on peripheral VA-ECMO weaning in patients with refractory cardiogenic shock [33]. The survival rate at 30 days was increased in patients receiving levosimendan only in the unmatched analysis [33].

In the current study, we used a propensity score analysis with a choice of variables to include based upon a comparison of baseline characteristics between the two groups, inputs from both literature and clinical expertise. No statistical difference in any of the included covariates was found between the 126 matched patients. One of the covariates included in the propensity score was the potential for myocardial recovery based upon indications for VA-ECMO. Indeed, outcomes of patients undergoing VA-ECMO greatly differ regarding the reason for ECMO implantation [17–26]. Forty-two patients who received ECMO less than 48 h were excluded because we considered the probability to receive levosimendan was too low. Patients with refractory cardiac arrest were also excluded because of a high-mortality rate in our institution [26] and the specific pathophysiology of post-cardiac arrest syndrome. In a large observational study, the rate of successful weaning in 4658 patients with cardiogenic shock was reported to be limited to 65.7% [30], a result pretty similar to our findings.

**Limitations**

Our study suffers several obvious limitations such as its observational nature and a possible lack of power due to the low number of patients included in the matched analysis. Although we have used propensity score matching to reduce selection bias, there is still a risk that our two groups may not be comparable due to the presence of confounding variables not accounted for in our model (unknown or unmeasured confounders) [34]. Thus, the results observed here may not be reproducible within the scope of a randomized controlled trial (RCT). More broadly, observational studies and RCT can generate heterogeneous or even conflicting results [35]. Given this limitation, our findings should be viewed cautiously and call for future clinical research using a more robust design. Moreover, in the levosimendan group, 34.8% of patients presented a TAPSE < 12 mm at ICU admission compared to 29.1% in the control group. Although not significant, this result may suggest a higher proportion of patients with right ventricular dysfunction in the levosimendan group and may have contributed to limit the effect of levosimendan on VA-ECMO weaning success in patients presenting bi-ventricular failure [36]. Also, we observed an increasing use of levosimendan over the most recent period with the risk that the variation in team performance over time may have led to minimize the drug effect on VA-ECMO weaning. Another main limitation is that administration of levosimendan occurred late after VA-ECMO implantation. This timing could be too late when compared with other studies [12, 33]. We postulate that physicians started levosimendan in a second step, only in patients demonstrating a weak probability of ECMO weaning success. Many arguments support that hypothesis. First, the duration of VA-ECMO was significantly longer in the levosimendan group in the unmatched analysis. Second, even if not statistically significant, a greater proportion of patients with a high potential for myocardial recovery did not receive levosimendan (control group). Third, more patients in the levosimendan group had heart transplantation or LVAD. By contrast, levosimendan was administered only 3 days after VA-ECMO start in the study reported by Vally et al. [33], a shorter delay that may have contributed to their positive results. Finally, as a tertiary care university hospital with high

---

**Table 2 Balance of covariates before and after matching**

| Variable (mean)          | Unmatched* | Control (n = 128) | p  | Matched | Levosimendan (n = 48) | Control (n = 78) | p  |
|--------------------------|------------|-------------------|----|---------|-----------------------|------------------|----|
| Age (years)              | 53.9       | 52.6              | 0.575 | 54.3 | 54.7                 | 0.866            |
| Male (%)                 | 62         | 65                | 0.692 | 0.62 | 0.65                 | 0.785            |
| Potential for recovery   | 2.32       | 2.12              | 0.104 | 2.31 | 2.35                 | 0.747            |
| SAPS-II                  | 53.5       | 51.7              | 0.424 | 52.7 | 52.1                 | 0.824            |
| SOFA                     | 11.5       | 11.8              | 0.530 | 11.3 | 11.5                 | 0.687            |
| LVEF (%)                 | 18         | 20.2              | 0.241 | 18   | 17                   | 0.690            |
| VA-ECMO duration (days)  | 10.6       | 6.5               | <0.001 | 10.8 | 10.2                 | 0.478            |
| Serum lactate level (mmol/L) | 64       | 7.5               | 0.178 | 6.3  | 6.1                  | 0.816            |

**Myocardial recovery potential:** High 1 Intermediate 2, Low 3

SAPS-II: simplified acute physiology score, SOFA: sequential organ failure assessment, LVEF: left ventricular ejection fraction. Data are expressed as mean. The p value refers to a comparison between the levosimendan group and the control group. *Compared to the entire cohort (n = 200), the unmatched population had 176 patients since there were 24 patients with missing data on some of the variables used in the analysis.
Conclusion
In conclusion, the current study found no benefit to levosimendan in order to reduce VA-ECMO weaning failure in a population of patients with surgical and medical refractory cardiogenic shocks. Facing the discordance between the most recent data, there is an urgent need for a large randomized clinical trial which could bring more reliable information regarding the interest of levosimendan in that clinical setting, if any.

Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.1186/s13054-020-03122-y.

Additional file 1.

Abbreviations
Cis: Confidence intervals; ICU: Intensive care unit; LVAD: Left ventricular assist device; LVEF: Left ventricular ejection fraction; ORs: Odds ratios; RCT: Randomized controlled trial; RPM: Rotation per minute; SAPS-II: Simplified acute physiology score; ScvO₂: Central venous oxygen saturation; SOFA: Sequential organ failure assessment; TAPSE: Tricuspid annular plane systolic excursion; VA-ECMO: Veno-arterial extracorporeal membrane oxygenation

Acknowledgements
Not applicable

Authors’ contributions
Conception of the study: EG, MJL, and JLF; Data recording: EG and MP; Statistical analysis: MJL, FA, and XA; Redaction of the manuscript: EG, MJL, and JLF. The authors read and approved the final manuscript.

Funding
None

Availability of data and materials
The data used and/or analyzed in the present study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
This study was approved by the Institutional Review Board of the Hospices Civils de Lyon (CE N°20-54). The need for informed consent was waived because of the observational and retrospective nature of the study.

Consent for publication
Not applicable.

Competing interests
JLF is a member of an advisory board working for ORION Pharma France and has received honoraria from the company for his participation in the board.

Author details
1Hospices Civils de Lyon, Hôpital Louis Pradel, Service d’Anesthésie-Réanimation, Lyon, France. 2INSERM U1060, Laboratoire CarMeN, HU OPeRa, Lyon, France. 3Hospices Civils de Lyon, Hôpital Louis Pradel, Service de Chirurgie Cardiaque, Lyon, France. 4Nuffield Department of Primary care, Oxford University, Oxford, UK. 5Lyon School of Pharmacy (ISP8), Public Health department/UMR CNRS 5510 MATEIS, I2B Team, Lyon, France. 6Division of Health Sciences, Warwick Medical School, Warwick university, Coventry, UK.

References
1. Ventetuolo CE, Muratore CS. Extracorporeal life support in critically ill adults. Am J Respir Crit Care Med. 2014;190:497–508.
2. Extracorporeal Life Support Organization. ELSO guidelines for adult cardiac failure v1.3. Michigan, USA, 2015. http://www.elsol.org/Resources/Guidelines.aspx. Accessed 1 July 2015.
3. Allou N, Lo Pinto H, Persichini R, Bouchet B, Braunberger E, Lugagne N, et al. Cannula-related infection in patients supported by peripheral ECMO: clinical and microbiological characteristics. ASAIO J. 2019;65(2):180–6.
4. Aubron C, DePuydt J, Belen F, Bailey M, Schmidt M, Sheldrake J, et al. Predictive factors of bleeding events in adults undergoing extracorporeal membrane oxygenation. Ann Intensive Care. 2016;6(1):97.
5. Trudzinski FC, Minko P, Rapp D, Fährndich S, Haake H, Haab M, et al. Runtime and aPTT predict venous thrombosis and thromboembolism in patients on extracorporeal membrane oxygenation: a retrospective analysis. Ann Intensive Care. 2016;6(1):66.
6. Levy B, Bastien O, Katin B, Cariou A, Chouïched T, Combes A, Mebazaa A, Megarbane B, Plaisance P, Ouattara A, Spaulding C, Tueliboul J, Vanhuyse F, Boulian T, Kuteifan K. Experts’ recommendations for the management of adult patients with cardiacogenic shock. Ann Intensive Care. 2015;5(1):52.
7. Ellender T, Skinner J. The use of vasopressors and inotropes in the emergency medical treatment of shock. Emerg Med Clin N Am. 2008;26:759–86.
8. Halkala H, Kavola J, Nissinen E, Wall P, Levijoki J, Lindén IB. Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan. J Mol Cell Cardiol. 1995;27:1859–66.
9. Erdel N, Papp Z, Pollesello P, et al. The levosimendan metabolite OR-1896 elicits vasodilation by activating the K (ATP) and BK (Ca) channels in rat isolated arterioles. Br J Pharmacol. 2006;148:696–702.
10. Pathak A, Lebrin M, Vaccaro A, Senard JM, Despas F. Pharmacology of levosimendan: inotropic, vasodilatory and cardioprotective effects. J Clin Pharm Ther. 2013;38(5):341–9. https://doi.org/10.1111/jcpt.12067 Epub 2013 Apr 18.
11. Cholley B, Levy B, Fellahi J, Longrois D, Amour J, Ouattara A, Mebazaa A. Levosimendan in the light of the results of the recent randomized controlled trials: an expert opinion paper. Crit Care. 2019;23(1):385.
12. Distelmaier K, Roth C, Schnurka L, et al. Beneficial effects of levosimendan on survival in patients undergoing extracorporeal membrane oxygenation after cardiovascular surgery. Br J Anaesth. 2016;117:52–8.
13. Sangalli F, Avalli L, Laratta M, et al. Effects of levosimendan on endothelial function and hemodynamics during weaning from venoarterial extracorporeal life support. J Cardiothorac Vasc Anesth. 2016;30:1449–53.
14. van Diepen S, Katz JN, Albert NM, Henry TD, Jacobs AK, Kapur NK, Klicic JA, Menon V, Ohrman EM, Sweitzer NK, Thiele H, Washam JB, Cohen MG. Contemporary management of cardiogenic shock: a scientific statement from the American Heart Association. Circulation. 2017;136:e232–68.
15. Aissaou N, Luyt CE, Leprince P, Trouillet JL, Léger P, Pavie A, et al. Predictors of successful extracorporeal membrane oxygenation (ECMO) weaning after assistance for refractory cardiogenic shock. Intensive Care Med. 2011;37:1738–45.
16. Jacky A, Rudiger A, Krüger B, et al. Comparison of levosimendan and milrinone for ECLS weaning in patients after cardiac surgery—a retrospective before and after study. J Cardiothorac Vasc Anesth. 2018;32:2112–9.
17. Cheng R, Hachamovitch R, Kittleson M, Patel J, Arabia F, Moriguchi J, Poldermans D, Maggioni AP, Poldermans D. Expert consensus on levosimendan: a systematic review and meta-analysis. J Am Coll Cardiol. 2015;66:2632–46.
18. Menon V, Ohman EM, Sweitzer NK, Thiele H, Washam JB, Cohen MG. Contemporary management of cardiogenic shock: a scientific statement from the American Heart Association. Circulation. 2017;136:e232–68.
19. Aissaou N, Luyt CE, Leprince P, Trouillet JL, Léger P, Pavie A, et al. Predictors of successful extracorporeal membrane oxygenation (ECMO) weaning after assistance for refractory cardiogenic shock. Intensive Care Med. 2011;37:1738–45.
20. Jacky A, Rudiger A, Krüger B, et al. Comparison of levosimendan and milrinone for ECLS weaning in patients after cardiac surgery—a retrospective before and after study. J Cardiothorac Vasc Anesth. 2018;32:2112–9.
21. Cheng R, Hachamovitch R, Kittleson M, Patel J, Arabia F, Moriguchi J, Poldermans D, Maggioni AP, Poldermans D. Expert consensus on levosimendan: a systematic review and meta-analysis. J Am Coll Cardiol. 2015;66:2632–46.
22. Menon V, Ohman EM, Sweitzer NK, Thiele H, Washam JB, Cohen MG. Contemporary management of cardiogenic shock: a scientific statement from the American Heart Association. Circulation. 2017;136:e232–68.
23. Aissaou N, Luyt CE, Leprince P, Trouillet JL, Léger P, Pavie A, et al. Predictors of successful extracorporeal membrane oxygenation (ECMO) weaning after assistance for refractory cardiogenic shock. Intensive Care Med. 2011;37:1738–45.
24. Jacky A, Rudiger A, Krüger B, et al. Comparison of levosimendan and milrinone for ECLS weaning in patients after cardiac surgery—a retrospective before and after study. J Cardiothorac Vasc Anesth. 2018;32:2112–9.
20. Muller G, Flecher E, Lebreton G, Luyt CE, Trouillet JL, Bréchot N, Schmidt M, Mastroianni C, Chastre J, Leprince P, Anselmi A, Combes A. The ENCOURAGE mortality risk score and analysis of long-term outcomes after VA-ECMO for acute myocardial infarction with cardiogenic shock. Intensive Care Med. 2016;42(3):370–8.

21. Pabst D, Foy AJ, Peterson B, Soleimani B, Brehm CE. Predicting survival in patients treated with extracorporeal membrane oxygenation after myocardial infarction. Crit Care Med. 2018;46(5):e359–63.

22. Biancari F, Perrotti A, Dalen M, Guerrieri M, Fiore A, Reichart D, Dell’Aquila AM, Gatti G, Ala-Kokko T, et al. Meta-analysis of the outcome after postcardiotomy venoarterial extracorporeal membrane oxygenation in adult patients. J Cardiothorac Vasc Anesth. 2018;32(3):1175–82.

23. Dangers L, Bréchot N, Schmidt M, Lebreton G, Hékimian G, Nieszelskowska A, Besset S, Trouillet JL, Chastre J, Leprince P, Combes A, Luyt CE. Extracorporeal membrane oxygenation for acute decompensated heart failure. Crit Care Med. 2017;45(8):1359–66.

24. Ouweneel DM, Schotborgh JV, et al. Extracorporeal life support during cardiac arrest and cardiogenic shock: a systematic review and meta-analysis. Intensive Care Med. 2016;42(12):1922–34.

25. Pozzi M, Bottin C, Armoiry X, Sebbag L, Boissonnat P, Hugon-Vallet E, Koffel C, Flamens C, Paulus S, Fellahi JL, Obadia JF. Extracorporeal life support for primary graft dysfunction after heart transplantation. Interact Cardiovasc Thorac Surg. 2018;27(5):778–84.

26. Pozzi M, Armoiry X, Achanza F, Koffel C, Pavlovic I, Lavigne F, Fellahi JL, Obadia JF. Extracorporeal life support for refractory cardiac arrest: a 10-year comparative analysis. Ann Thorac Surg. 2019;107(3):809–16.

27. Sascha O. Becker and Andrea Ichino. Estimation of average treatment effects based on propensity scores February 2002 Stata Journal 2(4):358–377.

28. Leuven, E., and B. Stanesi. 2003. “PSMATCH2: Stata module to perform full Mahalanobis and propensity score matching, common support graphing, and covariate imbalance testing, version 4.0.6”).

29. Lee HS, Kim HS, Lee SH, Lee SA, Hwang JJ, Park JB, Kim YH, Moon HJ, Lee WS. Clinical implications of the initial SAPS II in veno-arterial extracorporeal oxygenation. J Thorac Dis. 2019;11(1):68–83.

30. Asso S, Matsui H, Fushimi K, Yasunaga H. In-hospital mortality and successful weaning from venoarterial extracorporeal membrane oxygenation: analysis of 5263 patients using a national inpatient database in Japan. Crit Care. 2016;20(80).

31. Smith M, Vukomanovc A, Brodie D, Thiaagarajan R, Rycus P, Buscher H. Duration of veno-arterial extracorporeal life support (VA ECMO) and outcome: an analysis of the Extracorporeal Life Support Organization (ELSO) registry. Crit Care. 2017;21(1):43.

32. Affronti A, di Bella L, Carino D, et al. Levosimendan may improve weaning outcomes in venoarterial ECMO patients. ASAIO J. 2013;59:554–7.

33. Vally S, Ferdynus C, Perschini R, Bouchet B, Braunberger E, Lo Pinto H, Martinet O, Vandreux D, Aujout T, Allyn J, Allou N. Impact of levosimendan on weaning from peripheral venoarterial extracorporeal membrane oxygenation in intensive care unit. Ann Intensive Care. 2019;9(1):24.

34. Nuttall QA, Houle TF. Liars, damn liars, and propensity scores. Anesthesiology. 2008;108(1):3–4.

35. Armoiry X, Obadia JF, et al. Comparison of transcatheter versus surgical aortic valve implantation in high-risk patients: a nationwide study in France. J Thorac Cardiovasc Surg. 2018;156(3):1017–1025.e4.

36. Pappalardo F, Pieri M, et al. Timing and strategy for weaning from venoarterial ECMO are complex issues. J Cardiothorac Vasc Anesth. 2015;29(4):906–11.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.